The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

<p>Abstract</p> <p>Background</p> <p>No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatme...

Full description

Bibliographic Details
Main Authors: Samson Rebecca S, Tozer Daniel J, Wheeler-Kingshott Claudia AM, Webber Daniel J, Barber Kelly, Richardson Karen, He Xiao-Ling, Crawley Charles, Scott Michael A, Patani Rickie, Kolappan Madhan, Connick Peter, Thomas David L, Du Ming-Qing, Luan Shi L, Michell Andrew W, Altmann Daniel R, Thompson Alan J, Miller David H, Compston Alastair, Chandran Siddharthan
Format: Article
Language:English
Published: BMC 2011-03-01
Series:Trials
Online Access:http://www.trialsjournal.com/content/12/1/62

Internet

http://www.trialsjournal.com/content/12/1/62

Similar Items